Kura Oncology, Inc. (KURA) financial statements (2022 and earlier)

Company profile

Business Address 12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments517,960633,320236,891178,98593,14567,79085,746
Cash and cash equivalents90,672325,49326,13516,11911,4339,72515,443
Short-term investments427,288307,827210,756162,86681,71258,06570,303
Receivables  30224216295430
Other undisclosed current assets4,3293,9722,6821,9881,280725693
Total current assets:522,289637,292239,603181,19794,64168,81086,869
Noncurrent Assets
Operating lease, right-of-use asset5,5736,334 
Property, plant and equipment2,6732,02144(92)104071
Restricted cash and investments210210     
Other noncurrent assets3,3061,3552,3251,1821,200971314
Other undisclosed noncurrent assets   92  5
Total noncurrent assets:11,7629,9202,3691,1821,2101,011390
TOTAL ASSETS:534,051647,212241,972182,37995,85169,82187,259
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22,45523,02415,31413,3858,2844,6814,118
Accounts payable3,2362,7533,5263,8901,248638902
Accrued liabilities1,0731,5051,1245088392,136 
Employee-related liabilities7,9237,0163,6943,4372,3451,9071,282
Other undisclosed accounts payable and accrued liabilities10,22311,7506,9705,5503,852 1,934
Debt 3,000250 1,531  
Derivative instruments and hedges, liabilities      232
Other undisclosed current liabilities   230216770705
Total current liabilities:22,45526,02415,56413,61510,0315,4515,055
Noncurrent Liabilities
Long-term debt and lease obligation4,6129,8887,2507,5005,5677,324 
Long-term debt, excluding current maturities 4,2507,2507,5005,5677,324 
Operating lease, liability4,6125,638 
Liabilities, other than long-term debt375395377279388170101
Other liabilities375395377279388170101
Total noncurrent liabilities:4,98710,2837,6277,7795,9557,494101
Total liabilities:27,44236,30723,19121,39415,98612,9455,156
Stockholders' equity
Stockholders' equity attributable to parent506,609610,905218,781160,98579,86556,87682,103
Common stock7754322
Additional paid in capital941,359913,354431,322310,849169,201110,748108,484
Accumulated other comprehensive income (loss)(1,789)46331(131)(49)(18)(87)
Accumulated deficit(432,968)(302,502)(212,877)(149,737)(89,290)(53,856)(26,296)
Total stockholders' equity:506,609610,905218,781160,98579,86556,87682,103
TOTAL LIABILITIES AND EQUITY:534,051647,212241,972182,37995,85169,82187,259

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(131,258)(91,899)(67,479)(62,883)(36,077)(28,367)(23,865)
Operating loss:(131,258)(91,899)(67,479)(62,883)(36,077)(28,367)(23,865)
Nonoperating income7922,2744,3392,4366438071,240
Investment income, nonoperating    751499128
Interest and debt expense(212)(578)(580)(498)(888) (42)
Net loss:(130,678)(90,203)(63,720)(60,945)(36,322)(27,560)(22,667)
Other undisclosed net income attributable to parent212578580498888 42
Net loss available to common stockholders, diluted:(130,466)(89,625)(63,140)(60,447)(35,434)(27,560)(22,625)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(130,678)(90,203)(63,720)(60,945)(36,322)(27,560)(22,667)
Other comprehensive income (loss)(1,835)(285)462(82)   
Comprehensive loss:(132,513)(90,488)(63,258)(61,027)(36,322)(27,560)(22,667)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent21257858049885769(45)
Comprehensive loss, net of tax, attributable to parent:(132,301)(89,910)(62,678)(60,529)(35,465)(27,491)(22,712)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: